Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Prolarix (tretazicar co-administered with caricotamide)

Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression

Trial Locations (1)

1200

Cliniques Universitaires Saint-Luc, Brussels

Sponsors
All Listed Sponsors
lead

BTG International Inc.

OTHER

NCT00746590 - Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter